AstraZeneca v. Laurus Labs: BRILINTA® Ticagrelor Patent Settled in 78 Days
AstraZeneca brought a patent infringement action against Laurus Labs and its US generic subsidiary over proposed generic versions of BRILINTA® (ticagrelor) in 90 mg and 60 mg dosage strengths. The parties reached a negotiated settlement culminating in a consent judgment and injunction — all within just 78 days of filing.
Swift consent judgment ends AstraZeneca’s BRILINTA® generic challenge
On 11 April 2024, AstraZeneca AB and AstraZeneca Pharmaceuticals LP filed suit in the Delaware District Court against Laurus Labs Limited and its US affiliate Laurus Generics Inc., asserting infringement of US10300065B2. The patent covers ticagrelor formulations marketed under the BRILINTA® brand in both 90 mg and 60 mg dosage strengths — a blockbuster oral antiplatelet agent used to reduce cardiovascular events in patients with acute coronary syndrome.
The case closed on 28 June 2024 — just 78 days after filing — through a consent judgment and injunction. Rather than a judicial ruling on the merits of infringement or validity, the parties negotiated a settlement agreement and jointly stipulated to entry of judgment and an injunction against Laurus. This mechanism is common in Hatch-Waxman ANDA litigation and typically signals that the generic entrant has agreed to market exclusion terms in exchange for a negotiated entry date or other commercial concessions.
The 78-day resolution timeline is notably fast even by ANDA litigation standards, suggesting AstraZeneca moved quickly to enforce and Laurus elected not to contest the patent’s validity or infringement. The specific terms of the underlying settlement agreement — including any agreed generic entry date — are not disclosed in the public record. What is clear is that the consent injunction provides AstraZeneca with enforceable market protection for BRILINTA® against Laurus’s proposed generic product, at least for the duration specified in the confidential settlement.
Filing to Consent Judgment in 78 days
78 days — well below the typical 2–3 year ANDA litigation timeline, signalling swift settlement
Consent judgment and injunction: what the resolution means for both parties
Consent judgment: settlement crystallised as a court order
A consent judgment is a court-entered order reflecting the parties’ agreed terms. Unlike a merits ruling, it does not adjudicate infringement or validity — but it carries the same enforcement weight as a litigated judgment. AstraZeneca now holds an injunction against Laurus that is enforceable as a court order, not merely a private contract.
Enforceable without merits rulingAstraZeneca secures injunction protecting BRILINTA® market
The consent judgment and accompanying injunction prevent Laurus from commercialising its generic ticagrelor product without AstraZeneca’s authorisation. The underlying settlement agreement likely specifies a permitted entry date — a standard Hatch-Waxman resolution tool. The confidentiality of that date means competitors and payers cannot predict the exact timeline for Laurus-sourced generic availability.
Market exclusivity preservedLaurus accepts injunction — entry date likely conditioned on settlement terms
By consenting to judgment and injunction rather than mounting an invalidity or non-infringement defence, Laurus forecloses a near-term launch. In ANDA litigation, generic challengers typically accept such terms when patent strength and litigation cost calculus favour negotiation over contest. The confidential settlement likely grants Laurus a defined future entry window in exchange for this concession.
Launch constrained by consent termsUS10300065B2 remains a credible enforcement tool against further generics
A consent judgment does not bind other generic filers or confirm patent validity, but AstraZeneca’s ability to resolve this case swiftly signals strong enforcement posture around US10300065B2. Other ANDA filers targeting BRILINTA® should treat this outcome as an indicator that AstraZeneca will litigate promptly and has negotiating leverage — particularly relevant for any generic entrants who have not yet filed Paragraph IV certifications.
Strong enforcement signal to generic filersFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | AstraZeneca AB | Individual | Global biopharmaceutical company — holder of US10300065B2 covering BRILINTA® ticagrelorSearch in Eureka ↗ |
| Co-Plaintiff | Astrazeneca Pharmaceuticals, LP | Company | Search in Eureka ↗ |
| Defendant | Laurus Labs, Ltd. | Company | Indian generic pharmaceutical manufacturer and its US subsidiary, Laurus Generics Inc.Search in Eureka ↗ |
| Co-Defendant | Laurus Generics Inc. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Alexandra M. Joyce | Attorney | Counsel for AstraZeneca ABSearch in Eureka ↗ |
| Plaintiff counsel | Daniel M. Silver | Attorney | Counsel for AstraZeneca ABSearch in Eureka ↗ |
| Plaintiff law firm | McCarter & English LLP | Law Firm | Representing AstraZeneca ABSearch in Eureka ↗ |
| Presiding judge | Judge Richard G. Andrews | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The consent judgment stipulates joint agreement to entry of judgment and an injunction — it reflects a negotiated commercial resolution, not a judicial finding on infringement or validity. The phrasing ‘agreed to terms and conditions representing a negotiated settlement’ confirms the disposition is entirely contractual in origin. The scope of the injunction, and particularly any agreed generic entry date, remains non-public, limiting external analysis of the commercial concessions made by either party.
US10300065B2 — Ticagrelor formulations for BRILINTA® 90 mg and 60 mg
US10300065B2, filed under application number US15/546626, covers ticagrelor formulations — the active pharmaceutical ingredient in AstraZeneca’s BRILINTA® brand. BRILINTA® is a P2Y12 platelet inhibitor approved to reduce cardiovascular events in patients with acute coronary syndrome and prior myocardial infarction. The patent’s coverage of both the 90 mg and 60 mg dosage strengths is commercially significant, as these represent the full approved dosage range in the US market.
From a competitive standpoint, US10300065B2 functions as a formulation-layer protection strategy — extending the defensible IP perimeter around ticagrelor beyond the base compound. For generic manufacturers, this type of formulation patent is a common but material obstacle in ANDA filings, requiring either a Paragraph IV invalidity argument or design-around. AstraZeneca’s rapid enforcement and Laurus’s consent to judgment suggests the patent presents credible barriers. Any company developing or considering a generic ticagrelor programme should conduct a targeted FTO analysis against this patent’s claim scope before progressing an ANDA filing.
Should you run an FTO analysis against US10300065B2?
Any pharmaceutical company actively developing or considering an ANDA filing for generic ticagrelor tablets — at either 90 mg or 60 mg dosage strengths — should treat US10300065B2 as a primary clearance target. AstraZeneca’s demonstrated willingness to file and rapidly obtain injunctive relief means the cost of a missed FTO gap is exceptionally high. Contract development organisations (CDOs) formulating ticagrelor equivalents face similar exposure if they supply ANDA applicants.
PatSnap Eureka’s FTO Search Agent allows R&D and regulatory teams to map the claim scope of US10300065B2 against proposed formulation parameters, identify prosecution history estoppel, and surface related family members or continuation applications that may extend protection. Eureka also flags co-pending ANDA litigations involving the same patent, giving portfolio managers a real-time picture of AstraZeneca’s enforcement activity across all generic challengers — an essential input for any go/no-go decision on a ticagrelor generic programme.
Run a freedom-to-operate analysis on US10300065B2 to assess your product’s exposure
Run FTO in Eureka →Similar ANDA patent infringement cases involving cardiovascular formulation patents
Explore comparable Hatch-Waxman infringement actions filed in the Delaware District Court involving branded cardiovascular drug formulation patents and generic challengers.
What this case signals for the cardiovascular generics IP landscape
AstraZeneca’s 78-day enforcement record against Laurus sets a clear precedent for how it will defend BRILINTA® formulation patents.
Swift consent judgments signal a well-prepared patentee litigation playbook
When a brand pharmaceutical company resolves an ANDA suit within 78 days via consent judgment, it typically indicates pre-filing preparation and a strong patent position. AstraZeneca’s rapid resolution with Laurus suggests US10300065B2 presented sufficient validity and infringement arguments to deter a full defence. Generic entrants and their counsel should assess this patent carefully before filing further Paragraph IV certifications.
Injunction-backed settlements create asymmetric risk for subsequent ANDA filers
While this consent judgment does not legally bind other generic challengers, it establishes AstraZeneca’s willingness and speed to litigate and obtain injunctive relief. Subsequent filers face a patentee with a live injunction precedent and demonstrated litigation efficiency. This raises the effective cost and risk threshold for any competitor considering a Paragraph IV challenge to US10300065B2 for ticagrelor formulations.
AB v Laurus — key questions answered
The case was resolved via consent judgment and injunction on 28 June 2024, 78 days after filing. The parties negotiated a settlement agreement and jointly stipulated to entry of judgment. No merits ruling on infringement or validity was issued. The specific terms of the settlement, including any agreed generic entry date, are not disclosed in the public record.
AstraZeneca asserted US10300065B2 (application number US15/546626), covering ticagrelor tablet formulations in 90 mg and 60 mg dosage strengths — the doses marketed under the BRILINTA® brand. The case is consistent with standard Hatch-Waxman ANDA enforcement practice targeting a proposed generic version of those dosage forms.
The consent judgment includes an injunction against Laurus Labs Limited and Laurus Generics Inc., preventing commercialisation of their generic ticagrelor product without AstraZeneca’s authorisation. In Hatch-Waxman practice, such settlements typically incorporate a confidential agreed entry date allowing the generic entrant to launch at a future point, though those terms are not publicly disclosed in this case.
The consent judgment does not legally bind other ANDA filers or constitute a judicial validity finding on US10300065B2. However, it signals AstraZeneca’s aggressive and efficient enforcement posture. Other generic filers targeting BRILINTA® dosage forms should consider this outcome when assessing litigation risk and the relative merits of Paragraph IV certification versus design-around or settlement strategies.
Yes. Because the case resolved through consent rather than a merits adjudication, US10300065B2’s validity has not been judicially assessed. The patent remains eligible for IPR petitions at the USPTO from any party that has not been served with a complaint for more than one year. Generic challengers who believe the formulation claims are vulnerable may find the IPR route a lower-cost alternative to district court litigation.
PatSnap Eureka searches patents and litigation data to answer instantly.